CD133, a cancer stem cell marker and confers malignant stemness [22], is upregulated in Caco2 and HCT116 cells with 40 and 100 ng rhIL-23 treatment compared to vehicle-treated cells (Figure 2C; Figure S2C). Here, PROM1 is linked to cancer.